PE20150725A1 - Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este - Google Patents

Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este

Info

Publication number
PE20150725A1
PE20150725A1 PE2014002029A PE2014002029A PE20150725A1 PE 20150725 A1 PE20150725 A1 PE 20150725A1 PE 2014002029 A PE2014002029 A PE 2014002029A PE 2014002029 A PE2014002029 A PE 2014002029A PE 20150725 A1 PE20150725 A1 PE 20150725A1
Authority
PE
Peru
Prior art keywords
formulations
compound
methods
forms
compositions
Prior art date
Application number
PE2014002029A
Other languages
English (en)
Inventor
Paroma Chakravarty
Sanjeev Kothari
Francis Gosselin
Scott J Savage
Jeffrey Stults
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48539412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150725(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20150725A1 publication Critical patent/PE20150725A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se describen monoclorhidrato de (S)-2-(4-clorofenil)-1-(4-((5R,7R)-7-hidroxi-5-metil-6,7-dihidro-5H-ciclopenta [d]pirimidin-4-il)piperazin-1-il)-3-(isopropilamino)propan-1-ona ( un compuesto de formula I), formas, formulaciones, composiciones farmaceuticas, procesos de fabricacion y metodos de uso; los cuales son utiles entre otros como anticancerigenos.
PE2014002029A 2012-05-17 2013-05-17 Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este PE20150725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261648536P 2012-05-17 2012-05-17

Publications (1)

Publication Number Publication Date
PE20150725A1 true PE20150725A1 (es) 2015-05-17

Family

ID=48539412

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002029A PE20150725A1 (es) 2012-05-17 2013-05-17 Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este

Country Status (31)

Country Link
US (2) US9290458B2 (es)
EP (2) EP2858989B9 (es)
JP (2) JP6283663B2 (es)
KR (5) KR20200074252A (es)
CN (1) CN104470912B (es)
AU (2) AU2013262548B2 (es)
BR (1) BR112014028593A2 (es)
CA (1) CA2873663C (es)
CL (1) CL2014003115A1 (es)
CO (1) CO7151489A2 (es)
CR (1) CR20140560A (es)
DK (1) DK2858989T3 (es)
ES (1) ES2799512T3 (es)
HK (1) HK1208462A1 (es)
HR (1) HRP20200992T1 (es)
HU (1) HUE051254T2 (es)
IL (2) IL235712B (es)
LT (1) LT2858989T (es)
MA (1) MA37650A1 (es)
MX (1) MX353041B (es)
MY (1) MY170086A (es)
NZ (1) NZ702513A (es)
PE (1) PE20150725A1 (es)
PH (1) PH12014502538A1 (es)
PL (1) PL2858989T3 (es)
PT (1) PT2858989T (es)
RS (1) RS60417B9 (es)
RU (1) RU2650511C2 (es)
SG (1) SG11201407618VA (es)
SI (1) SI2858989T1 (es)
WO (1) WO2013173811A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
CN112898210A (zh) 2013-11-15 2021-06-04 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
EP2946774B1 (en) 2014-05-19 2020-04-22 Tillotts Pharma AG Modified release coated capsules
KR20230124110A (ko) * 2016-08-10 2023-08-24 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
WO2021030248A1 (en) * 2019-08-12 2021-02-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
JP2024520798A (ja) * 2021-06-09 2024-05-24 ロンザ・ベンド・インコーポレーテッド 非晶質固体分散体の調製のための噴霧乾燥のための混合溶媒
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (en) 1993-12-12 1995-06-15 Yigal Cohen A novel method to protect plants from fungal infection
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
US7582766B2 (en) 2003-06-09 2009-09-01 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2486181C2 (ru) 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
ES2422733T3 (es) * 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
EA020151B1 (ru) 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
KR20130058672A (ko) * 2010-04-16 2013-06-04 제넨테크, 인크. ＰＩ3Ｋ/ＡＫＴ 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 ＦＯＸＯ３ａ
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
RU2643146C2 (ru) 2012-05-17 2018-01-31 Дженентек, Инк. Способ получения аминокислотных соединений
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
CA2901577A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES

Also Published As

Publication number Publication date
RU2650511C2 (ru) 2018-04-16
ES2799512T3 (es) 2020-12-18
CN104470912B (zh) 2017-11-14
JP6283663B2 (ja) 2018-02-21
PT2858989T (pt) 2020-06-25
RS60417B9 (sr) 2021-07-30
CN104470912A (zh) 2015-03-25
HUE051254T2 (hu) 2021-03-01
MX2014013856A (es) 2015-02-18
KR20220143143A (ko) 2022-10-24
MX353041B (es) 2017-12-18
CA2873663C (en) 2020-01-14
NZ702513A (en) 2016-09-30
IL272037B (en) 2020-10-29
WO2013173811A1 (en) 2013-11-21
MY170086A (en) 2019-07-04
RU2014151016A (ru) 2016-07-10
KR20240066293A (ko) 2024-05-14
SI2858989T1 (sl) 2020-08-31
JP2018062536A (ja) 2018-04-19
AU2017279607C1 (en) 2019-05-16
HK1208462A1 (en) 2016-03-04
US9505725B2 (en) 2016-11-29
KR20150020200A (ko) 2015-02-25
US20150274677A1 (en) 2015-10-01
SG11201407618VA (en) 2015-01-29
EP3719014A1 (en) 2020-10-07
IL272037A (en) 2020-02-27
AU2017279607A1 (en) 2018-01-18
AU2013262548A1 (en) 2015-01-15
DK2858989T3 (da) 2020-06-02
MA37650A1 (fr) 2016-11-30
BR112014028593A2 (pt) 2017-12-19
US9290458B2 (en) 2016-03-22
CL2014003115A1 (es) 2015-07-03
KR20200074252A (ko) 2020-06-24
CO7151489A2 (es) 2014-12-29
PH12014502538B1 (en) 2015-01-21
PL2858989T3 (pl) 2020-11-16
US20160152575A1 (en) 2016-06-02
PH12014502538A1 (en) 2015-01-21
RS60417B1 (sr) 2020-07-31
EP2858989A1 (en) 2015-04-15
IL235712B (en) 2020-01-30
HRP20200992T1 (hr) 2020-10-16
IL235712A0 (en) 2015-02-01
KR20210095238A (ko) 2021-07-30
AU2017279607B2 (en) 2018-11-22
LT2858989T (lt) 2020-08-10
KR102125588B1 (ko) 2020-06-22
CR20140560A (es) 2015-01-12
EP2858989B1 (en) 2020-05-06
JP6518352B2 (ja) 2019-05-22
AU2013262548B2 (en) 2017-09-21
JP2015517533A (ja) 2015-06-22
CA2873663A1 (en) 2013-11-21
EP2858989B9 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
PE20150725A1 (es) Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
CY1118860T1 (el) Νεα διαζασπειροκυκλοαλκανια και αζασπειροκυκλοαλκανια
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CL2014002301A1 (es) Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras.
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
PH12015500263A1 (en) New bicyclic derivatives
ECSP15032846A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboximida
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
PE20150332A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de cinasa
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
AR094997A1 (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
CR20170438A (es) Desacetoxitubulisina h y análogos de esta
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
CL2014003123A1 (es) 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FD Application declared void or lapsed